Evidence map›Paper›PMID 33073533›Full record

ArticleFEBS open bio2020

The rapid endocytic uptake of fetuin-A by adherent tumor cells is mediated by Toll-like receptor 4 (TLR4).

Portia L Thomas, Gladys Nangami, Tanu Rana, Adam Evans, Stephen D Williams, Dylan Crowell, Anil Shanker, Amos M Sakwe, Josiah Ochieng

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. The Role of Fetuin-A in Tumor Cell Growth, Prognosis, and Dissemination.International journal of molecular sciences · 2024
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Portia L ThomasDepartment of Microbiology, Immunology and Physiology, Meharry Medical College, Nashville, TN, USA.
Gladys NangamiDepartment of Biochemistry, Cancer Biology, Pharmacology and Neuroscience, Meharry Medical College, Nashville, TN, USA.
Tanu RanaDepartment of Biochemistry, Cancer Biology, Pharmacology and Neuroscience, Meharry Medical College, Nashville, TN, USA.
Adam EvansDepartment of Biochemistry, Cancer Biology, Pharmacology and Neuroscience, Meharry Medical College, Nashville, TN, USA.
Stephen D WilliamsDepartment of Microbiology, Immunology and Physiology, Meharry Medical College, Nashville, TN, USA.
Dylan CrowellDepartment of Biochemistry, Cancer Biology, Pharmacology and Neuroscience, Meharry Medical College, Nashville, TN, USA.
Anil ShankerDepartment of Microbiology, Immunology and Physiology, Meharry Medical College, Nashville, TN, USA.
Amos M SakweSchool of Graduate Studies and Research, Meharry Medical College, Nashville, TN, USA.
Josiah OchiengDepartment of Biochemistry, Cancer Biology, Pharmacology and Neuroscience, Meharry Medical College, Nashville, TN, USA.ORCID 0000-0003-4551-5174
Meharry Medical College · US

Funding

Endowment for Health Disparities ResearchS21MD000104 · NIMHD · MEHARRY MEDICAL COLLEGE · PI HILDRETH, JAMES E · 2001 to 2016
$73.1M
The RCMI Program in Health Disparities Research at Meharry Medical College - SupplementU54MD007586 · NIMHD · MEHARRY MEDICAL COLLEGE · PI Maureen Sanderson · 2017 to 2026
$48.2M
Technologies and Resources CoreU54MD007593 · NIMHD · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2012 to 2018
$24.7M
THE MEHARRY RISE INITIATIVER25GM059994 · NIGMS · MEHARRY MEDICAL COLLEGE · PI MOTLEY-JOHNSON, EVANGELINE D · 1999 to 2021
$23.0M
Translational Pathology CoreU54CA163069 · NCI · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2011 to 2025
$18.8M
Role of Fus1-mediated antitumor CD8T-NK crosstalk in Alzheimer's disease pathologySC1CA182843 · NCI · MEHARRY MEDICAL COLLEGE · PI SHANKER, ANIL · 2013 to 2020
$3.1M
Notch ligands in regulation of anti-cancer immunityR01CA175370 · NCI · OHIO STATE UNIVERSITY · PI CARBONE, DAVID P., DIKOV, MIKHAIL M · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA175370NCI NIH HHS SC1 CA182843NCI NIH HHS U54 CA163069NIGMS NIH HHS R25 GM059994NIMHD NIH HHS S21 MD000104NIMHD NIH HHS U54 MD007586NIMHD NIH HHS U54 MD007593
6 · The paper itself

Abstract

Fetuin-A is a serum glycoprotein synthesized and secreted into blood by the liver and whose main physiological function is the inhibition of ectopic calcification. However, a number of studies have demonstrated that it is a multifunctional protein. For example, endocytic uptake of fetuin-A by tumor cells resulting in rapid cellular adhesion and spreading has been reported. The precise uptake mechanism, however, has been elusive. The present studies were done to determine whether Toll-like receptor-4 (TLR4), which has been previously shown to be a receptor for fetuin-A and is commonly expressed in immune cells, could take part in the rapid uptake (< 3 min) of fetuin-A by tumor cells. Rapid uptake of fetuin-A was inhibited by the specific TLR4 inhibitor CLI-095 and also attenuated in TLR4 knockdown prostate tumor cells. Inhibition of TLR4 by CLI-095 also attenuated the rapid adhesion of tumor cells as well as invasion through a bed of Matrigel. The data suggest mechanisms by which TLR4 modulates the adhesion and growth of tumor cells.

Indexed as

alpha-2-HS-GlycoproteinCell AdhesionCell Line, TumorEndocytosisHumansToll-Like Receptor 4alpha-2-HS-GlycoproteinTLR4 protein, humanToll-Like Receptor 4adhesionendocytosisfetuin-ALPSreceptorTLR4

Identifiers

PMID33073533
PMCPMC7714080
OpenAlexW3093421889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.